Digestive system disorders: Gastroesophageal reflux disease

Western Journal of Medicine

Volumn 173, Issue 1, 2000, Pages 48-53

  Katzka, David A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ARTICLE; BARRETT ESOPHAGUS; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMAN; INCIDENCE; PREVALENCE; STOMACH FUNDOPLICATION; SURGICAL TECHNIQUE;

ENZYME INHIBITORS; FUNDOPLICATION; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; ION PUMPS; LAPAROSCOPY; RECURRENCE; TREATMENT OUTCOME;

EID: 0033949449     PISSN: 00930415     EISSN: None     Source Type: Journal    
DOI: 10.1136/ewjm.173.1.48     Document Type: Article

References (39)

1. Isolauri J, Luostarinen M, Isolauri E, Reinikatnen P, Viljakka M, Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997;92:37-41.
2. Richter JE. Extraesophageal manifestations of gastroesophageal reflux disease. Clin Perspect 1998;1:28-39.
3. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-1810.
4. Richter JE, Sabesin SM, Kogut DG, Kerr RM, Wruble LD, Coller, MJ. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease. Am J Gastroenterol 1996;91:1766-1772.
5. Robinson M, Decktor DL, Maton PN, et al. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis. Aliment Pharmacol Ther 1993;7:67-73.
6. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121:161-167.
7. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis: a controlled double blind trial of their efficacy and safety. Gut 1994;35:590-598.
8. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-1110.
9. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-1022.
10. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylon is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997;112:707-717.
11. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis: results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993;28:224-228.
12. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease: the European Rabeprazole Study Group. Aliment Pharmacol Ther 1999;13:49-50.
13. Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans: the Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 1992;326:786-792.
14. Martinez de Haro LF, Ortiz A, Parrilla P, Garcia Marcilla JA, Aguayo JL, Morales G. Long-term results of Nissen fundoplication in reflux esophagitis without strictures: clinical, endoscopic, and pH-metric evaluation. Dig Dis Sci 1992;37:523-527.
15. Bjerkeset T, Edna TH, Fjosne U. Long-term results after "floppy" Nissen/Rosetti fundoplication for gastroesophageal reflux disease. Scand J Gastroenterol 1992;27:707-710.
16. Luostarinen M, Isolauri J, Laitinen J, et al. Fate of Nissen fundoplication after 20 years: a clinical, endoscopical, and functional analysis. Gut 1993;34:1015-1020.
17. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:859-867.
18. Lundell L, Dalenback J, Hattlebakk J, et al. Omeprazole or antireflux surgery in the long term management of gastroesophageal reflux disease: results of a multicenter, randomized clinical trial [abstract]. Gastroenterology 1998;114:A207.
19. Leite L, Johnston B, Just R, Castell DO. Persistent acid secretion during omeprazole therapy; a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996;91:1527-1531.
20. Bate CM, Green JRB, Axon ATR, et al. Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying esophagitis. Aliment Pharmacol Ther 1998;12:41-47.
21. Bate CM, Green JR, Axon AT, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic esophagitis. Aliment Pharmacol Ther 1997;11:755-763.
22. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-773.
23. Revicki DA, Sorensen S, Maton PN, Orlando RC. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesuphageal reflux disease. Dig Dis 1998;16:284-291.
24. Wiklund I, Bardhan KD, Muller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine: results from a multicentre clinical trial. Ital J Gastroenterol Hepatol 1998;30:19-27.
25. Sampliner RK, Garewal HS, Fennerty MB, Aickin M. Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 1990;35:93-96.
26. Williamson WA, Ellis FH Jr, Gibb SP, Shahian DM, Aretz T. Effect of antireflux operation on Barrett's mucosa, Ann Thorac Surg 1990;49:537-542.
27. Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993;7:623-628.
28. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994;89:1844-1848.
29. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92:582-585.
30. Sagar PM, Ackroyd R, Hosie KB, et al. Regression and progression of Barrett's esophagus after antireflux surgery. Br J Surg 1995;82:806-810.
31. Csendes A, Braghetto I, Burdiles P, et al. Long-term results of classic antireflux surgery in 152 patients with Barrett's esophagus: clinical, radiologic, endoscopic, manometric and acid reflux test analysis before and late after operation. Surgery 1998;123:645-657.
32. Kim R, Baggott BB, Rose S, et al. Quantitative endoscopy: precise computerized measurement of metaplastic epithelial surface area in Barrett's esophagus. Gastroenterology 1995;108:360-366.
33. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Squamous islands in Barrett's esophagus: what lies underneath? Am J Gastroenterol 1998;93:332-335.
34. Teichtahl H, Kronborg IJ, Yeomans ND, Robinson P. Adult asthma and gastro-oesophageal reflux: the effects of omeprazole therapy on asthma. Aust N Z J Med 1996;26:671-676.
35. Harding SM, Richter JE, Guzzo MR, et al. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 1996;100:395-405.
36. Ekstrom T, Lindgren BR, Tibbling L. Effects of ranitidine treatment on patients with asthma and a history of gastro-oesophageal reflux: a double blind crossover study. Thorax 1989;44:19-23.
37. Larrain A. Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux. Chest 1991;99:1330-1335.
38. Spechler SJ, Gordon DW, Cohen J, Williford WO, Krol W. The effects of antireflux therapy on pulmonary function in patients with severe gastroesophageal reflux disease: Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. Am J Gastroenterol 1995;90:915-918.
39. Hanson DG, Kamel PL, Kahrilas PJ. Outcomes of antireflux therapy in the treatment of chronic laryngitis. Ann Otol Rhinol Laryngol 1995;104:550-555.